REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Announces Retirement of Board Member

MaxCyteAnnouncement

23/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241223:nRSW0232Ra&default-theme=true

RNS Number : 0232R  MaxCyte, Inc.  23 December 2024

 

MaxCyte Announces Retirement of Board Member Art Mandell

 

ROCKVILLE, MD, December 23, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OmYwNWQ6Nzc0M2M2OWIzNmM3NGRlZWJjMjVhZTA2Yzg5MTAyODg1ZGU1YjVmNWZmM2RkNGUzNGMyM2NjNjNkMjg0NWI3ZTpwOlQ6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell therapeutics, today announced
that Art Mandell has retired from his position as a member of the Board of
Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on
the Board since 2006 and has been an integral part of MaxCyte's growth and
strategic direction. Upon Mr. Mandell's retirement, MaxCyte will have nine
directors.

 

During Mr. Mandell's tenure, MaxCyte has achieved significant milestones
including its initial public offering on the UK AIM exchange and US Nasdaq
Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic
Platform Licenses with cell and gene therapy biotech companies and supporting
the industry's first, FDA-approved, CRISPR edited non-viral cell therapy.

 

"We are deeply grateful for Art's exceptional leadership, scientific insights
and valuable contributions over the years," said Richard Douglas, chairman of
the Board. "Art's perspective and guidance have been instrumental in
positioning MaxCyte as a leader in cell engineering."

 

"It has been a privilege to serve on the Board of MaxCyte," said Mr. Mandell.
"I am proud of all that we have accomplished together, and I am confident in
the Company's bright future providing highly differentiated technology
solutions that enable the development of novel cell and gene therapies."

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OmYwNWQ6Nzc0M2M2OWIzNmM3NGRlZWJjMjVhZTA2Yzg5MTAyODg1ZGU1YjVmNWZmM2RkNGUzNGMyM2NjNjNkMjg0NWI3ZTpwOlQ6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OjUzYmM6ZWE0YzMwNTdkYjBmZDljOTFiNWNhY2YwNjg0Y2JkOWY0YTE1MGU4NmJiMjhkOGEzYjcxZWUwY2QyNDE0MGVjNzpwOlQ6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OmJlNjE6MDg5YTJkYzkxYmJmMDllZmQ3ODMzZWRlYzQyZDU4N2JlMjY3MDczM2EyMzFmY2QzMGEwNTE1YjBlZmI5MDAwZDpwOlQ6Rg)
.

 

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

 

US Media Relations

Spectrum Science
Jordan Vines
+1 540-629-3137

jvines@spectrumscience.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=e3vxer2NIGe6s6dEuww7ZyeICIouyXQ0zSoiilKjWQm4n2xxVLeDycAIEFAaeQ-w1Nc3ahSZYWKeEVFOmjh8EMux6Ef0Ttd9Aq6FMo1Kea4Zln5SjxZwlwJkFJrGBzMp___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OjJkMTE6YjdlMmVjOWM2YjNjYTk4NDA4YjgwNWIxYzZjYzFmNjY2NGRmNjNhMGEzZjk4Y2ZiMmQwNmMyOTM1YjM3NGJjOTpwOlQ6Rg)

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@icrhealthcare.com

 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.  All statements other than statements of historical facts contained
in this press release, including statements regarding our future results of
operations or financial condition, business strategy and plans and objectives
of management for future operations, are forward-looking statements. These
statements are inherently uncertain, and investors are cautioned not to unduly
rely on these statements.

 

Risks and uncertainties related to our business are described in greater
detail in Item 1A  of our Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the Securities and Exchange Commission ("SEC")
on March 12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings that we make
with the Securities and Exchange Commission from time to time, including in
our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on
November 6, 2024. These documents are available through the Investor Menu,
Financials section, under "SEC Filings" on the Investors page of our website
at http://investors.maxcyte.com
(https://protect.checkpoint.com/v2/___http:/investors.maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzpkZDk1YjdlNmUwNjcxNDQyNDkwMDMyNDVhNjZjNzdjYTo2OjE3YzQ6ZjhiMDg5NTBjYTMxZDVmNzlkZjhiZjEyMjIzMmYwZjE2NzNlMDlhOTRiOTc5MmI3NThjNGE5NjQ2MDE3ZjAyMTpwOlQ6Rg)
. Any forward-looking statements in this press release are based on our
current beliefs and opinions on the relevant subject based on information
available to us as of the date of such press release, and you should not rely
on forward-looking statements as predictions of future events. We undertake no
obligation to update any forward-looking statements made in this press release
to reflect events or circumstances after the date of this press release or to
reflect new information or the occurrence of unanticipated events, except as
required by law.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMZMZZFZVGDZM